Each year in this country, physicians prescribe medications to treat ADHD in nearly 3 million children. The safety of these agents has been the subject of some debate.
Here to discuss the issue of the cardiovascular safety of stimulants, atomoxetine(Drug information on atomoxetine), and alpha-agonists used to manage ADHD is Joan Daughton, MD, Assistant Professor of Child Psychiatry at the University of Nebraska Medical Center in Omaha. Dr Daughton is also Training Director of the Creighton-Nebraska Child and Adolescent Psychiatry Training Program and Post Pediatrics Portal Program at the University of Nebraska Medical Center.
Dr Daughton also details the essentials of a baseline assessment and cardiovascular evaluation before ADHD therapy is initiated and briefly reviews scientific statements issued jointly by the American Heart Association and American Academy of Pediatrics on the overall safety of medications to treat ADHD and specifically in children with underlying cardiovascular abnormalities.
• Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896-1904. http://www.nejm.org/doi/full/10.1056/NEJMoa1110212. Accessed October 17, 2012.
• Treatment of ADHD in children with tics: a randomized controlled trial. Tourette's Syndrome Study Group. Neurology. 2002;58:527-536.
• Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;118;2407-2423.
• Erratum in: Circulation. 2009;120:e55-9.